Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Teva Jumps Most in Two Weeks on FDA Clearance of Cancer Drug

Feb. 29 (Bloomberg) -- Teva Pharmaceutical Industries Ltd. jumped the most in two weeks after its Pharmachemie BV unit was approved by the U.S. Food & Drug Administration to sell preservative-free methotrexate, a treatment for cancer.

The shares advanced 2.2 percent, the biggest intraday gain since Feb. 15, to 170.40 shekels at 12:39 p.m. in Tel Aviv.

To contact the reporter on this story: Gwen Ackerman in Jerusalem at gackerman@bloomberg.net

To contact the editor responsible for this story: Claudia Maedler at cmaedler@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.